| 1 |
Suzuki J, Takaku A. Cerebrovascular "Moyamoya" disease. Disease showing abnormal net-like vessels in base of brain [J]. Arch Neurol, 1969, 20(3): 288-299.
|
| 2 |
Fukui M. Guidelines for the diagnosis and treatment of spontaneous occlusion of the circle of Willis ('Moyamoya' disease). Research Committee on Spontaneous Occlusion of the Circle of Willis (Moyamoya Disease) of the Ministry of Health and Welfare, Japan [J]. Clin Neurol Neurosurg, 1997, 99 Suppl 2: S238-S240.
|
| 3 |
Ikeda H, Sasaki T, Yoshimoto T, et al. Mapping of a familial Moyamoya disease gene to chromosome 3p24.2-p26 [J]. Am J Hum Genet, 1999, 64(2): 533-537.
|
| 4 |
Inoue TK, Ikezaki K, Sasazuki T, et al. Linkage analysis of Moyamoya disease on chromosome 6 [J]. J Child Neurol, 2000, 15(3): 179-182.
|
| 5 |
Sakurai K, Horiuchi Y, Ikeda H, et al. A novel susceptibility locus for Moyamoya disease on chromosome 8q23 [J]. J Hum Genet, 2004, 49(5): 278-281.
|
| 6 |
Yamauchi T, Tada M, Houkin K, et al. Linkage of familial Moyamoya disease (spontaneous occlusion of the circle of Willis) to chromosome 17q25 [J]. Stroke, 2000, 31(4): 930-935.
|
| 7 |
Liu W, Morito D, Takashima S, et al. Identification of RNF213 as a susceptibility gene for Moyamoya disease and its possible role in vascular development [J]. PLoS One, 2011, 6(7): e22542.
|
| 8 |
Hitomi T, Habu T, Kobayashi H, et al. Downregulation of Securin by the variant RNF213 R4810K (rs112735431, G>A) reduces angiogenic activity of induced pluripotent stem cell-derived vascular endothelial cells from Moyamoya patients [J]. Biochem Biophys Res Commun, 2013, 438(1): 13-19.
|
| 9 |
Duan L, Wei L, Tian Y, et al. Novel susceptibility loci for Moyamoya disease revealed by a genome-wide association study [J]. Stroke, 2018, 49(1): 11-18.
|
| 10 |
De Las Rivas J, Fontanillo C. Protein-protein interactions essentials: key concepts to building and analyzing interactome networks [J]. PLoS Comput Biol, 2010, 6(6): e1000807.
|
| 11 |
Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life [J]. Nucleic Acids Res, 2015, 43(Database issue): D447-D452.
|
| 12 |
Shen W, Song Z, Zhong X, et al. Sangerbox: a comprehensive, interaction-friendly clinical bioinformatics analysis platform [J]. iMeta, 2022, 1(3): e36.
|
| 13 |
Scott RM, Smith JL, Robertson RL, et al. Long-term outcome in children with Moyamoya syndrome after cranial revascularization by pial synangiosis [J]. J Neurosurg, 2004, 100(2 Suppl Pediatrics): 142-149.
|
| 14 |
宋晓雯, 张谦, 赵继宗. 烟雾病流行病学研究进展 [J/OL].中华脑血管病杂志(电子版). 2021, 15(1): 9-15.
|
| 15 |
Scott RM, Smith ER. Moyamoya disease and Moyamoya syndrome [J]. N Engl J Med, 2009, 360(12): 1226-1237.
|
| 16 |
Grangeon L, Guey S, Schwitalla JC, et al. Clinical and molecular features of 5 European multigenerational families with Moyamoya angiopathy [J]. Stroke, 2019, 50(4): 789-796.
|
| 17 |
Kamada F, Aoki Y, Narisawa A, et al. A genome-wide association study identifies RNF213 as the first Moyamoya disease gene [J]. J Hum Genet, 2011, 56(1): 34-40.
|
| 18 |
Malek AM, Connors S, Robertson RL, et al. Elevation of cerebrospinal fluid levels of basic fibroblast growth factor in Moyamoya and central nervous system disorders [J]. Pediatr Neurosurg, 1997, 27(4): 182-189.
|
| 19 |
Takagi Y, Kikuta K, Nozaki K, et al. Expression of hypoxia-inducing factor-1 alpha and endoglin in intimal hyperplasia of the middle cerebral artery of patients with Moyamoya disease [J]. Neurosurgery, 2007, 60(2): 338-345; discussion 345.
|
| 20 |
Nanba R, Kuroda S, Ishikawa T, et al. Increased expression of hepatocyte growth factor in cerebrospinal fluid and intracranial artery in Moyamoya disease [J]. Stroke, 2004, 35(12): 2837-2842.
|
| 21 |
Ueno M, Kira R, Matsushima T, et al. Moyamoya disease and transforming growth factor-beta1 [J]. J Neurosurg, 2000, 92(5): 907-908.
|
| 22 |
Yoshimoto T, Houkin K, Takahashi A, et al. Angiogenic factors in Moyamoya disease [J]. Stroke, 1996, 27(12): 2160-2165.
|
| 23 |
Soriano SG, Cowan DB, Proctor MR, et al. Levels of soluble adhesion Molecules are elevated in the cerebrospinal fluid of children with Moyamoya syndrome [J]. Neurosurgery, 2002, 50(3): 544-549.
|
| 24 |
Lu J, Wang J, Lin Z, et al. MMP-9 as a biomarker for predicting hemorrhagic strokes in Moyamoya disease [J]. Front Neurol, 2021, 12: 721118.
|
| 25 |
Kitano S, Sakamoto H, Fujitani K, et al. Moyamoya disease associated with a brain stem glioma [J]. Childs Nerv Syst, 2000, 16(4): 251-255.
|
| 26 |
Janda PH, Bellew JG, Veerappan V. Moyamoya disease: case report and literature review [J]. J Am Osteopath Assoc, 2009, 109(10): 547-553.
|
| 27 |
Mukheem Mudabbir MA, Ramineni KK, Krishna Reddy GV, et al. Moyamoya angiopathy in a case of carcinoma colon [J]. Neurol India, 2022, 70(5): 2213-2214.
|
| 28 |
Lim M, Cheshier S, Steinberg GK. New vessel formation in the central nervous system during tumor growth, vascular malformations, and Moyamoya [J]. Curr Neurovasc Res, 2006, 3(3): 237-245.
|
| 29 |
Islam MK, Islam MR, Rahman MH, et al. Bioinformatics strategies to identify shared molecular biomarkers that link ischemic stroke and Moyamoya disease with glioblastoma [J]. Pharmaceutics, 2022, 14(8): 1573.
|
| 30 |
Mikami T, Suzuki H, Komatsu K, et al. Influence of inflammatory disease on the pathophysiology of Moyamoya disease and Quasi-Moyamoya disease [J]. Neurol Med Chir (Tokyo), 2019, 59(10): 361-370.
|
| 31 |
Asselman C, Hemelsoet D, Eggermont D, et al. Moyamoya disease emerging as an immune-related angiopathy [J]. Trends Mol Med, 2022, 28(11): 939-950.
|
| 32 |
Kanamori F, Yokoyama K, Ota A, et al. Transcriptome-wide analysis of intracranial artery in patients with Moyamoya disease showing upregulation of immune response, and downregulation of oxidative phosphorylation and DNA repair [J]. Neurosurg Focus, 2021, 51(3): E3.
|
| 33 |
Li H, Zhang ZS, Dong ZN, et al. Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with Moyamoya disease: a case-control study [J]. Stroke, 2011, 42(4): 1138-1139.
|
| 34 |
Chen JB, Lei D, He M, et al. Clinical features and disease progression in Moyamoya disease patients with Graves disease [J]. J Neurosurg, 2015, 123(4): 848-855.
|
| 35 |
Fujimura M, Sonobe S, Nishijima Y, et al. Genetics and biomarkers of Moyamoya disease: significance of RNF213 as a susceptibility gene [J]. J Stroke, 2014, 16(2): 65-72.
|